在严重联合免疫缺陷（WB - SCID）小鼠模型中对重组白细胞介素 - 2免疫疗法治疗人血管肉瘤的评估。
Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID).
作者信息
Masuzawa M, Mochida N, Amano T, Fujimura T, Hamada Y, Tamauchi H, Sakurai Y, Nishiyama S, Katsuoka K
机构信息
Department of Dermatology, School of Medicine, Kitasato University, Sagamihara-shi, Kanagawa-ken 228-8555, Japan.
出版信息
J Dermatol Sci. 2001 Oct;27(2):88-94. doi: 10.1016/s0923-1811(01)00103-7.
We treated the patients with cutaneous hemangiosarcoma with recombinant interleukin-2 (rIL-2) immunotherapy that showed clear therapeutic effects. This immunotherapy is popular for the treatment of hemangiosarcoma in Japan. The purpose of this study is to clarify the clinical effects in an animal experiment. After establishing a SCID mouse model of human hemangiosarcoma WB-SCID, we used this model to investigate anti-tumor effects of rIL-2 and LAK cells. We demonstrated that hemangiosarcoma cells are LAK-sensitive, and LAK cells induced by rIL-2 suppress the growth of hemangiosarcoma. Our results may assure the clinical effects of rIL-2 immunotherapy on hemangiosarcoma.
我们采用重组白细胞介素-2（rIL-2）免疫疗法治疗皮肤血管肉瘤患者，该疗法显示出明显的治疗效果。这种免疫疗法在日本治疗血管肉瘤方面很受欢迎。本研究的目的是在动物实验中阐明其临床效果。在建立人血管肉瘤WB-SCID的SCID小鼠模型后，我们使用该模型研究rIL-2和LAK细胞的抗肿瘤作用。我们证明血管肉瘤细胞对LAK敏感，并且rIL-2诱导的LAK细胞可抑制血管肉瘤的生长。我们的结果可能证实rIL-2免疫疗法对血管肉瘤的临床效果。
Zotero 插件